Natco Pharma Ltd Corporate Actions

NATCO Pharma receives 7 observations from USFDA

 Copy Link

In a statement, NATCO Pharma stated it is confident of addressing all the observations within the stated time frame.

Top Stocks for Today - 20th June 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.

Natco Pharma Q4 Net Profit Rises 5% YoY to ₹406 Crore

 Copy Link

Quarterly revenue came in at ₹1,287.3 crore, a 16% YoY increase from ₹1,110.3 crore in Q4 FY24, led by robust performance in key segments.

Natco Pharma Gets USFDA Approval for Bosentan 32mg Tablets

 Copy Link

The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.

Natco Pharma Sells Telangana Land for ₹115.57 Crore

 Copy Link

The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations

Natco Pharma Q2 Profit Surges 83%, Declares Interim Dividend

 Copy Link

The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.

Natco Pharma settles US patent case over generic Ozempic

 Copy Link

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Cancer Patients Benefit as GST on Medications Slashed

 Copy Link

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Natco Pharma invests $8 million in US biotech firm eGenesis

 Copy Link

Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.